RecruitingPhase 3NCT04168502
Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML
Studying Acute promyelocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Intervention
- Gemtuzumab Ozogamicin(drug)
- Enrollment
- 414 enrolled
- Eligibility
- 18-60 years · All sexes
- Timeline
- 2020 – 2027
Study locations (30)
- A.O. - SS. Antonio e Biagio e Cesare Arrigo - SC Ematologia, Alessandria, Italy
- Aou Ospedali Riuniti "Umberto I - G.M. Lancisi - G. Salesi"- Ancona - Sod Clinica Ematologica, Ancona, Italy
- Area Vasta N. 5 Ascoli Piceno - S. Benedetto Del Tronto, Presidio Ospedaliero Av5 Osp. Gen. Prov.Le "C.G.Mazzoni" - Uoc Ematologia, Ascoli Piceno, Italy
- AO "San Giuseppe Moscati" - UOC Ematologia con unità di trapianto, Avellino, Italy
- AOU Consorziale Policlinico "Aldo Moro" - UO Ematologia con trapianto, Bari, Italy
- Policlinico S. Orsola - Malpighi - UOC Ematologia, Bologna, Italy
- Ao Sant'Anna E San Sebastiano - Caserta - Uoc Onco Ematologia, Caserta, Italy
- U.O.C. Oncoematologia - Istituto Oncologico Veneto Irccs, Presidio Ospedaliero S. Giacomo Apostolo, Castelfranco Veneto, Italy
- Asur Marche Area Vasta 3 - Presidio Ospedaliero Civitanova Marche - Uods Ematologia, Civitanova Marche, Italy
- Aou Arcispedale Sant'Anna - Cona (Fe) - Uoc Ematologia E Fisiopatologia Della Coagulazione, Cona, Italy
- Asst Di Cremona - Ospedale Di Cremona - Uo Ematologia, Cremona, Italy
- Aou Careggi - Firenze - Sod Ematologia, Florence, Italy
- Asl Frosinone, Ospedale F. Spaziani - Ematologia, Frosinone, Italy
- Irccs Aou San Martino - Genova - Uo Ematologia E Trapianti, Genova, Italy
- Presidio Ospedaliero Nord "Santa Maria Goretti" - UOC Ematologia, Latina, Italy
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04168502 on ClinicalTrials.govOther trials for Acute promyelocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07563179Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid LeukemiaShenzhen University General Hospital
- RECRUITINGPHASE3NCT07504458Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic LeukemiaQuetzal Therapeutics
- RECRUITINGPHASE3NCT07223814Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)Stichting Hemato-Oncologie voor Volwassenen Nederland
- ACTIVE NOT RECRUITINGNANCT07187505Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic LeukemiaAnhui Medical University
- RECRUITINGPHASE3NCT07503730Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL).First Affiliated Hospital Xi'an Jiaotong University
- ENROLLING BY INVITATIONNANCT06697327Daunorubicin + Cytarabine + Venetoclax in de Novo AMLAnhui Medical University
- RECRUITINGPHASE1NCT06313437Revumenib in Combination With 7+3 + Midostaurin in AMLRichard Stone, MD
- RECRUITINGPHASE3NCT06578247Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AMLDaiichi Sankyo